Press release
Antipsychotic Drugs Market Set for Robust Growth to USD 36.05 Billion by 2033, Led by North America's 39.8% Global Market Share | DataM Intelligence
The Antipsychotic Drugs Market size reached USD 16.41 Billion in 2024 and is expected to reach USD 36.05 Billion by 2033, growing at a CAGR of 9.2% during the forecast period 2025-2033.This robust growth is driven by the rising prevalence of mental health disorders such as schizophrenia and bipolar disorder, increasing awareness and diagnosis rates, and ongoing innovations in second- and third-generation antipsychotics with improved efficacy and reduced side effects. Government initiatives enhancing mental healthcare access, coupled with expanded therapeutic applications and demand from an aging population, further accelerate market expansion.
Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/antipsychotic-drugs-market?ram
United States: Key Industry Developments
✅ April 2025: Mezofy (aripiprazole), an oral film formulation, received FDA approval for treating schizophrenia in adults and patients aged 13 years and older, offering improved administration for better patient adherence.
Global: Key Industry Developments
✅ April 2025: The FDA approved Mezofy (aripiprazole) as an oral film for schizophrenia treatment in adults and adolescents aged 13+, highlighting advancements in third-generation antipsychotics with enhanced delivery methods.
✅ February 2025: Research advanced third-generation antipsychotics like aripiprazole and brexpiprazole through partial agonists at dopaminergic receptors, reducing side effects and improving psychosis management.
Key Merges and Acquisitions(2025):
✅ Moderna reports positive Phase 3 results for personalized cancer vaccine (Indirect Impact): In October 2025, Moderna and Merck announced promising Phase 3 study results for their personalized mRNA-based cancer vaccine. While an oncology treatment, this technological advancement in mRNA delivery has potential implications for future psychiatric treatments and showcases successful late-stage clinical development in 2025.
✅ FDA approves first-in-class treatment for a CNS disorder: In October 2025, the U.S. FDA approved a novel small molecule therapeutic for the treatment of a central nervous system (CNS) disorder, highlighting a favorable regulatory environment for innovative neurological and psychiatric drugs.
✅ Sanofi receives FDA approval for Wayrilz (Indirect Impact): In August 2025, the U.S. FDA approved Sanofi's Wayrilz. This demonstrates ongoing successful drug commercialization within the pharmaceutical sector that supports broader R&D efforts in high-cost areas like antipsychotics.
Market Segmentation Analysis:
-By Type: Second Generation Leads with Dominant Share
Second-generation antipsychotics hold approximately 50% market share as of 2024, favored for superior efficacy and reduced side effects like extrapyramidal symptoms compared to first-generation.
First-generation (typical) antipsychotics maintain a smaller 25% share, used for cost-effective schizophrenia control despite higher risks of motor side effects.
Third-generation antipsychotics, such as aripiprazole, capture 20% share, excelling in partial dopamine agonism for better patient compliance in bipolar and depression.
-By Indication: Schizophrenia Commands Largest Portion
Schizophrenia leads with 45% market share, driven by its chronic nature requiring lifelong therapy for positive and negative symptoms.
Bipolar disorder holds 25% share, leveraging antipsychotics for acute mania and maintenance alongside mood stabilizers.
Dementia (15%), depression (10%), and others (e.g., major depressive disorder) fill the rest, with growing off-label use in Alzheimer's agitation.
-By Route of Administration: Oral Overwhelmingly Dominant
Oral administration dominates with 80% share in 2024, preferred for convenience, daily dosing, and broad accessibility in outpatient settings.
Parenteral (injectable) accounts for 25% share, critical for non-adherent patients via long-acting formulations that ensure compliance in schizophrenia.
Purchase this report before year-end and unlock an exclusive 30% discount: https://www.datamintelligence.com/buy-now-page?report=antipsychotic-drugs-market?ram (Purchase 2 or more Reports and get 50% Discount)
Growth Drivers:
-Rising prevalence of mental health disorders such as schizophrenia, bipolar disorder, and psychosis worldwide.
-Increasing geriatric population more susceptible to mental illnesses.
-Growing awareness and improved diagnostic capabilities leading to higher diagnosis and treatment rates.
-Development of newer, more effective antipsychotics with fewer side effects and expanded therapeutic applications.
-Government initiatives and investments in mental health infrastructure, access, and awareness programs.
-Integration with digital health technologies and R&D investments by pharmaceutical companies.
Regional Insights:
-North America leads the antipsychotic drugs market with the highest share, estimated at around 39.8% in 2024, driven by high prevalence of psychiatric disorders like schizophrenia and bipolar disorder, advanced healthcare infrastructure, and strong presence of biopharmaceutical companies.
-Europe follows as the second-largest region, benefiting from established healthcare systems, increasing mental health awareness, and adoption of innovative therapies, though specific share figures vary across reports due to ongoing R&D and reimbursement policies.
-Asia Pacific ranks third in market share, fueled by rapid urbanization, growing mental health diagnoses, and expanding access to treatments in emerging economies like China and India, positioning it for faster future growth amid rising investments.
Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/antipsychotic-drugs-market?ram
Key Players:
Bayer AG | Teva Pharmaceutical Industries Ltd. | Dr. Reddy's Laboratories Ltd. | Hikma Pharmaceuticals PLC | Lupin | Cipla | Sanofi | AdvaCare Pharma | Wellona Pharma | Montage Laboratories Pvt. Ltd
Key Highlights (Top 5 Key Players) for Antipsychotic Drugs Market:
-Otsuka Pharmaceutical Co., Ltd. leads with significant contributions to the antipsychotic segment through innovative therapies like long-acting injectables, supporting overall market growth to US$36.05 billion by 2033.
-Dr. Reddy's Laboratories Ltd. drives market expansion via generics and new formulations, amid a projected CAGR of 9.2% from 2025-2033.
-Teva Pharmaceutical Industries Ltd. bolsters its position with broad antipsychotic portfolios, targeting rising demand in schizophrenia and bipolar disorder treatments.
-Hikma Pharmaceuticals PLC advances through affordable generics, contributing to North America's 39.8% market share in 2024.
-Sanofi supports growth with diversified mental health solutions, as the global market eyes steady rises driven by mental health awareness.
Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?ram
Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.
✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring
Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Antipsychotic Drugs Market Set for Robust Growth to USD 36.05 Billion by 2033, Led by North America's 39.8% Global Market Share | DataM Intelligence here
News-ID: 4297833 • Views: …
More Releases from DataM intelligence 4 Market Research LLP
Surgical Robotics Market to Reach US$15.25 Billion by 2033, Growing at 11.3% CAG …
Leander, Texas and Tokyo, Japan - Dec 02, 2025
According to DataM Intelligence, the global surgical robotics market reached US$5.84 billion in 2024 and is expected to reach US$15.25 billion by 2033, growing at a CAGR of 11.3% during the forecast period 2025-2033. This robust growth is propelled by increasing adoption of minimally invasive surgery, technological advancements in robotics and AI, growing prevalence of chronic diseases requiring complex procedures, rising demand…
Energy Management Systems Market to Grow at 13.58% CAGR Through 2031 | North Ame …
Leander, Texas and Tokyo, Japan - Dec 02, 2025
According to DataM Intelligence, the global energy management systems (EMS) market is estimated to grow at a CAGR of 13.58% during the forecast period 2024-2031. This significant growth is propelled by rising energy costs, stringent government regulations for energy efficiency, growing adoption of smart grid technologies, increasing corporate focus on sustainability and carbon footprint reduction, and advancements in IoT and data analytics…
Battery Material Market to Reach US$84.0 Billion by 2031, Growing at 6.0% CAGR | …
Leander, Texas and Tokyo, Japan - Dec 02, 2025
According to DataM Intelligence, the global battery material market reached US$52.6 billion in 2023 and is expected to reach US$84.0 billion by 2031, growing with a CAGR of 6.0% during the forecast period 2024-2031. This robust growth is propelled by the global transition to electric vehicles (EVs), massive expansion of grid energy storage, surging demand for consumer electronics, supportive government policies for…
Nanorobotics Market Size Growing at 18% CAGR by 2031 | North America Leads with …
Leander, Texas and Tokyo, Japan - Dec 02, 2025
According to DataM Intelligence, the global nanorobotics market, valued at US$7.8 billion in 2024, is projected to reach approximately US$24.8 billion by 2031 at a CAGR of 18% during the forecast period (2024-2031). This explosive growth is propelled by revolutionary advancements in targeted drug delivery, increasing investment in nanotechnology R&D, growing applications in precision medicine and surgery, rising prevalence of chronic diseases…
More Releases for Pharma
Miglitol Market Size, Share and Forecast By Key Players-Weiao Pharma, Zhejiang M …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Miglitol market is anticipated to grow at a compound annual growth rate (CAGR) of 11.49% between 2024 and 2031. The market is expected to grow to USD 22.32 Billion by 2024. The valuation is expected to reach USD 47.79 Billion by 2031.
The Miglitol market is experiencing significant growth due to the rising prevalence of diabetes and the increasing awareness of the…
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031.
The Dacarbazine market is projected to witness significant growth in the coming years, driven by increasing…
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031.
The dacarbazine market is experiencing steady growth, driven by the rising incidence of cancer globally. As…
Epilepsy Pipeline Assessment 2024: Therapies, Clinical Trials, and Market Insigh …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Epilepsy pipeline constitutes 75+ key companies continuously working towards developing 90+ Epilepsy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Epilepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the…
Global Indomethacin Market Seeking Excellent Growth by 2028 | Ratiopharm, Merck, …
"IBI has published a report entitled Global Indomethacin Market Research Report which provides comprehensive data on emerging trends, market drivers, growth opportunities, and barriers that could change the dynamics of the industry market. It provides an in-depth analysis of market segments which includes the product, application, and competitor analysis.
Click Here To Order A Sample Copy Of Indomethacin Global Market Report : https://www.infinitybusinessinsights.com/request_sample.php?id=380382
The Indomethacin Global Market Research Report provides close monitoring…
Roxatidine Market 2020: Top Companies Analysis To Grow Healthcare Business by 20 …
Business Industry Reports Research has recently announced a report on Global Roxatidine Market based on the Category Industry. The Roxatidine Market report emphasizes various key aspects, which include growth drivers, restraints, opportunities and recent market trends for the forecast period 2020-2024.
Global Roxatidine Market overview:
Business Industry Reports Analyst covers the Major Players data, including: shipment, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the…
